New drug cocktail aims to fight stomach cancer when first treatment fails
Disease control
Not yet recruiting
This clinical trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy (albumin-bound paclitaxel) as a second-line treatment for advanced stomach or gastroesophageal junction cancer. The study will enroll 30 adults whose cancer has wor…
Phase: NA • Sponsor: Qingxia Li • Aim: Disease control
Last updated Jun 26, 2026 16:32 UTC